查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1969411

主動脈瓣狹窄市場：按產品類型、瓣膜材質、年齡層和最終用戶分類 - 2026-2032 年全球預測

Aortic Stenosis Market by Product Type, Valve Material, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，主動脈瓣狹窄市場價值將達到 98.9 億美元，到 2026 年將成長至 109 億美元，到 2032 年將達到 199.3 億美元，年複合成長率為 10.51%。

主要市場統計數據
基準年 2025 98.9億美元
預計年份：2026年 109億美元
預測年份 2032 199.3億美元
複合年成長率 (%) 10.51%

本次演講將清楚闡述臨床技術的進步、人口結構的變化以及手術創新如何重塑所有相關人員。

主動脈瓣狹窄已從單純的外科手術問題發展成為一個涉及多方面的臨床和商業性領域，持續吸引臨床醫生、醫療設備開發商和醫療保健系統的關注。過去十年，經導管技術的進步、瓣膜設計和生物材料的改進以及手術全期護理路徑的完善，都促成了治療模式的轉變。因此，目前的治療方案在傳統外科手術和微創經導管治療之間取得了平衡，而患者的選擇、合併症的管理以及醫療機構的能力也日益影響著手術方案的選擇。

技術成熟、手術流程的廣泛採用以及支付主導以價值為中心的策略如何匯聚起來，從根本上改變主動脈瓣狹窄治療的臨床實踐和商業策略？

近年來，主動脈瓣狹窄治療領域發生了變革性變化，這源於技術的成熟、手術模式的演變以及相關人員期望的不斷提高。尤其值得注意的是，隨著醫療機構不斷最佳化患者分診和心臟團隊工作流程，經導管介入治療的興起。持續改進的器械進一步強化了這一趨勢，這些器械解決了瓣週漏、心律調節器使用率和輸送系統特性等挑戰。同時，對於某些解剖結構、年輕患者以及合併複雜疾病的患者，外科主動脈瓣置換術仍然至關重要。這兩種治療方法並存，需要在臨床和商業性策略上進行差異化。

對 2025 年美國關稅對設備採購、醫院採購行為和製造業韌性的營運、採購和策略影響進行多方面分析。

美國2025年實施的關稅政策為供應鏈、定價和採購帶來了複雜的變化，對醫療設備製造和醫療服務提供者的採購行為產生了影響。短期來看，關稅提高了進口零件和成品閥門系統的到岸成本，迫使製造商重新評估其籌資策略，並加快關鍵生產過程的近岸外包和本地化。因此，原始設備製造商（OEM）正在評估雙重採購協議、認證替代供應商並增加庫存緩衝，以降低供應中斷的風險。

將手術方法、瓣膜材料、醫療環境和年齡層與設備設計影響、訓練需求和採購優先事項連結起來的可操作細分分析。

深入的細分分析揭示了不同手術類型、材料、醫療機構和患者群體在應用模式和臨床需求多樣性方面的細微差異。依產品類型分類，可區分外科主動脈瓣置換術術和經導管主動脈瓣置換術（TAVR），其中外科手術方法又可根據瓣膜類型進一步分為球囊擴張型和自擴張式。經導管手術方法則進一步細分為經心尖入路和經股動脈路徑。經心尖入路包括左前胸切口和左前外側切口，而經股動脈路徑則分為經皮動脈入路和外科經股動脈路徑。這些差異會影響器械規格、操作者技能和手術全期計劃，從而對培訓項目和設備採購決策產生直接影響。

從區域觀點深入分析償還系統、基礎設施成熟度和人口趨勢如何影響全球技術、商業策略和區域夥伴關係的採用。

主動脈瓣狹窄治療的臨床啟動模式、監管預期和商業策略持續受到區域趨勢的影響。在美洲，儘管先進技術的應用和高病例量醫療機構的整合正在推進，但支付方主導的嚴格審查機制依然存在，並高度重視治療效果和成本效益。這種環境有助於建立持久的、循證的治療平台和整合式服務模式，從而減少住院時間和再入院風險。同時，在歐洲、中東和非洲，由於各國報銷制度的差異、專科醫療機構可及性的不均衡以及監管時間表的不同，情況呈現出顯著的多樣性，這為開展區域性臨床證據宣傳活動和與區域分銷商建立選擇性合作關係創造了機會。

對影響醫療保健領域採購決策和企業差異化的產品平台策略、服務模式和證據生成競爭考察。

主動脈瓣狹窄領域的競爭格局取決於產品改進、真實世界臨床證據的累積以及對綜合服務模式的持續投入。領先的製造商正致力於平台擴充性，以開發能夠適應各種解剖結構、入路和輸送系統的瓣膜系列，同時透過獨特的組織處理技術、抗鈣化技術以及降低手術複雜性的輸送導管人體工學設計來實現差異化。除了產品性能之外，企業提供全面的培訓、指導和上市後監測的能力也日益受到重視，這些服務能夠支援安全部署並最佳化不同臨床環境下的治療效果。

為經營團隊提供切實有效的建議，以加強價值鏈韌性，加快臨床部署，並透過實證夥伴關係向支付方證明價值。

產業領導者應採取整合策略方法，使產品創新與營運實際情況和支付方期望一致。首先，透過供應商多元化、關鍵零件近岸外包和策略性庫存管理，優先提升供應鏈韌性，既能確保產品按時上市，也能降低關稅和地緣政治風險。其次，投資於股動脈入路和複雜外科手術技術的臨床培訓和系統性指導項目，將加速安全應用，降低治療結果的差異性，並促使醫療機構更早採用這些技術。

我們採用透明的多來源調查方法，結合臨床文獻、註冊分析和相關人員訪談，提供檢驗的見解和可靠的策略指導。

本研究整合了臨床文獻、註冊登記資料以及對關鍵相關人員的訪談，旨在全面了解主動脈瓣狹窄治療的趨勢。調查方法結合了對同行評審的臨床研究和指南聲明的系統性回顧，以及對手術層面註冊登記和器械安全資料庫的分析，以捕捉手術趨勢和治療結果徵兆。為了補充定量資訊來源，研究人員還對介入性心臟病專家、心臟外科醫生、醫院採購經理、門診手術中心管理人員和醫療設備業高管進行了結構化訪談，以檢驗假設、識別運營限制並了解新興的臨床偏好。

這項簡潔而前瞻性的結論強調了產品、臨床和商業策略必須保持一致，才能將主動脈狹窄治療的創新轉化為可擴展的改進。

總之，主動脈瓣狹窄的治療格局呈現出臨床創新融合、手術方式偏好轉變以及所有相關人員日益關注價值的趨勢。外科手術和經導管治療的相互作用要求製造商和醫療服務提供者採取互補策略，以滿足解剖學特徵和以患者為中心的需求，同時簡化在不同治療環境中的部署。關稅和區域監管差異導致的供應鏈中斷進一步凸顯了適應性生產、穩健的供應商管理以及立足本地的商業化規劃的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 主動脈瓣狹窄市場：依產品類型分類

  • 外科主動脈瓣置換術
  • 經導管主動脈瓣置換術
    • 跨中心方法
      • 左側前側小切口開胸術
      • 左側前外側小切口開胸術
    • 經股骨入路
      • 經皮股動脈入路
      • 股動脈外科入路

第9章 主動脈瓣狹窄市場（依瓣膜材質分類）

  • 生物瓣膜
    • 源自牛
    • 源自豬
  • 機械閥
    • 籠球
    • 傾斜盤

第10章：主動脈瓣狹窄市場：依年齡層別分類

  • 成人版
  • 兒童

第11章 主動脈瓣狹窄市場：依最終用戶分類

  • 門診手術中心
  • 醫院
    • 當地醫院
    • 三好醫院

第12章 主動脈瓣狹窄市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 主動脈瓣狹窄市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 主動脈瓣狹窄市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國主動脈瓣狹窄市場

第16章：中國主動脈瓣狹窄市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 4C Medical Technologies, Inc.
  • Abbott Laboratories
  • AstraZeneca plc
  • B. Braun Melsungen AG
  • Biotronik
  • Boston Scientific Corporation
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • JenaValve Technology, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • LifeNet Health
  • LivaNova PLC
  • LivaNova PLC
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Venus Medtech（Hangzhou）Co., Ltd.
Product Code: MRR-535C629188E8

The Aortic Stenosis Market was valued at USD 9.89 billion in 2025 and is projected to grow to USD 10.90 billion in 2026, with a CAGR of 10.51%, reaching USD 19.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.89 billion
Estimated Year [2026] USD 10.90 billion
Forecast Year [2032] USD 19.93 billion
CAGR (%) 10.51%

A clear introduction to how clinical advances, demographic shifts, and procedural innovations are reshaping aortic stenosis care pathways and strategic priorities across stakeholders

Aortic stenosis has evolved from a narrowly defined surgical problem to a multifaceted clinical and commercial landscape drawing sustained attention from clinicians, device innovators, and health systems. Over the past decade, advances in transcatheter techniques, improvements in valve design and biomaterials, and refined peri-procedural care pathways have collectively shifted treatment paradigms. As a result, care delivery now balances long-established surgical approaches with less invasive transcatheter options, while patient selection, comorbidity management, and institutional capabilities increasingly dictate procedural choice.

Technological progress has not only expanded therapeutic options but has also altered training needs, capital planning, and procurement behaviors across hospitals and ambulatory centers. Simultaneously, demographic forces-principally population aging and higher prevalence of degenerative valvular disease-are driving sustained demand for durable, safe, and reproducible interventions. Clinicians are focusing on optimizing long-term outcomes through better valve sizing algorithms, imaging-guided implantation, and integrated heart team decision-making, thus tightening the link between device innovation and clinical practice.

Regulatory pathways and reimbursement frameworks continue to adapt to differentiated product profiles and real-world evidence, which reinforces the importance of rigorous clinical data and post-market surveillance. Taken together, these factors create a dynamic environment in which manufacturers, providers, and payers must align clinical value propositions with practical implementation strategies to succeed.

How technological maturation, procedural adoption, and payer-driven value imperatives are converging to fundamentally transform clinical practice and commercial strategy in aortic stenosis care

Recent transformative shifts in the aortic stenosis landscape are rooted in technological maturation, procedural adoption patterns, and evolving stakeholder expectations. The most visible change is the ascendancy of transcatheter approaches as centers refine patient triage and heart-team workflows; this trend has been reinforced by iterative device improvements that address paravalvular leak, pacemaker rates, and delivery system profiles. At the same time, surgical aortic valve replacement remains essential for specific anatomy, younger patients, and complex concomitant procedures, preserving a dual-modality continuum that demands differentiated clinical and commercial strategies.

Material science innovations have promoted the preferential use of biological valve materials in many adult populations while mechanical designs continue to serve niche indications; concurrently, valve architecture choices-such as balloon-expandable versus self-expanding platforms-have created distinct procedural profiles and training requirements. In parallel, value-based care imperatives and payer scrutiny are accelerating the adoption of protocols that shorten length of stay, enable same-day or next-day discharge where appropriate, and measure outcomes through standardized registries. These changes are prompting hospitals and ambulatory surgical centers to reassess capital investments, staff competencies, and vendor partnerships.

Moreover, global supply chain reconfigurations and regulatory harmonization efforts are encouraging manufacturers to invest in modular platform strategies and adaptable service models. As a result, new entrants and incumbent firms are placing greater emphasis on lifecycle management, incremental innovation, and evidence generation to support differentiated positioning in a rapidly evolving competitive arena.

Analyzing the multifaceted operational, procurement, and strategic consequences of United States 2025 tariffs on device sourcing, hospital purchasing behavior, and manufacturing resilience

The imposition of United States tariffs in 2025 has introduced a complex set of supply chain, pricing, and procurement dynamics that ripple across device manufacturing and institutional purchasing practices. In the near term, tariffs have increased the landed cost of imported components and finished valve systems, compelling manufacturers to reassess sourcing strategies and to accelerate nearshoring or regionalization of key production steps. Consequently, original equipment manufacturers are evaluating dual-sourcing agreements, qualifying alternate suppliers, and increasing inventory buffers to mitigate the risk of supply disruptions.

Hospitals and ambulatory surgical centers are responding by tightening procurement negotiations and exploring longer-term contracting to manage price volatility. In some instances, health systems are prioritizing devices with the most predictable total cost of care profiles, placing higher value on durable performance and reduced complication rates that lower downstream costs. Additionally, tariff-related cost pressures have stimulated greater collaboration between clinical teams and supply chain leaders to optimize device selection protocols and to adopt clinically driven standardization where appropriate.

Over time, the tariffs have also acted as a catalyst for strategic investment in domestic manufacturing capacity, leveraging public-private partnerships and targeted incentives. This shift can enhance resilience but may require substantial capital and time to scale. From a regulatory and competitive standpoint, tariffs have prompted more granular supplier qualification criteria and intensified the focus on lifecycle service offerings, training support, and bundled solutions that offset price increases through demonstrable clinical and operational efficiencies.

Actionable segmentation intelligence linking procedural approaches, valve materials, care settings, and age cohorts to device design implications, training needs, and procurement priorities

Insightful segmentation analysis reveals nuanced adoption patterns and differentiated clinical needs across procedural types, materials, care settings, and patient populations. By product type, the field distinguishes surgical aortic valve replacement from transcatheter aortic valve replacement, with surgical approaches further defined by valve type into balloon-expandable and self-expanding designs, while transcatheter therapy is subdivided into transapical and transfemoral approaches; within the transapical category practitioners deploy left anterior mini thoracotomy or left anterolateral mini thoracotomy techniques, and transfemoral access is categorized between percutaneous transfemoral and surgical transfemoral routes. These distinctions influence device specification, operator skill sets, and peri-procedural planning, and they have direct implications for training programs and capital procurement decisions.

Valve material segmentation also matters: biological valves, typically derived from bovine or porcine tissue, offer advantages in hemodynamics and avoid lifelong anticoagulation for many adult patients, whereas mechanical designs such as caged ball and tilting disc valves retain a role in carefully selected populations where durability is paramount. End user segmentation separates ambulatory surgical centers from hospitals; ambulatory centers, often structured as standalone clinics, emphasize throughput, standardized protocols, and rapid recovery pathways, while hospitals-which comprise community and tertiary facilities-manage a broader case mix, complex comorbidities, and integrated multidisciplinary care models. Finally, age group segmentation between adult and pediatric populations requires distinct device sizing, long-term planning, and follow-up strategies that shape both clinical pathways and product development priorities.

Deep regional perspectives on how reimbursement, infrastructure maturity, and demographic trends are influencing procedural adoption, commercial strategies, and local partnerships globally

Regional dynamics continue to shape clinical adoption patterns, regulatory expectations, and commercial strategies in aortic stenosis care. In the Americas, advanced procedural uptake and consolidation of high-volume centers coexist with payer-driven scrutiny that emphasizes outcomes and cost-effectiveness; this environment favors durable, evidence-backed platforms and integrated service models that reduce hospital length of stay and readmission risk. Conversely, Europe, Middle East & Africa exhibits heterogeneity driven by divergent national reimbursement frameworks, variable access to specialized centers, and differing regulatory timelines, which creates opportunities for tailored clinical evidence campaigns and selective partnerships with regional distributors.

In Asia-Pacific, expanding access to minimally invasive interventions, rapid infrastructure development in tertiary hospitals, and substantial investments in training are increasing the adoption of transcatheter therapies, while demographic trends-particularly aging populations in several regional markets-are elevating clinical demand. Across regions, supply chain considerations, tariff policies, and local manufacturing incentives are prompting companies to adapt product strategies and pricing approaches to align with regional procurement norms and institutional capabilities. As a result, successful commercial playbooks increasingly combine global platform consistency with localized training programs, registry participation, and health-economic evidence tailored to regional payer expectations.

Key competitive insights detailing how product platform strategies, service models, and evidence generation are shaping company differentiation and procurement decisions across care settings

Competitive dynamics in the aortic stenosis ecosystem are shaped by sustained investment in product improvement, real-world evidence generation, and integrated service models. Leading manufacturers are concentrating on platform extensibility-developing valve families that accommodate a broad range of anatomies, access routes, and delivery systems-while differentiating through proprietary tissue treatments, anti-calcification technologies, and delivery catheter ergonomics that reduce procedural complexity. In addition to product performance, companies are increasingly judged by their ability to provide comprehensive training, proctoring, and post-market surveillance that support safe adoption and optimize outcomes across diverse clinical settings.

Partnerships between device firms and clinical networks, as well as strategic alliances with imaging and software providers, are expanding the value proposition beyond a single implant to encompass pre-procedural planning, intra-procedural guidance, and longitudinal outcome tracking. Meanwhile, service-oriented offerings such as bundled pricing, outcome-linked contracts, and hybrid warranty models are emerging as competitive differentiators in procurement discussions. New entrants and established players alike must therefore synchronize R&D priorities with scalable manufacturing, robust supply chain governance, and credible evidence programs to sustain long-term commercial momentum.

Practical, high-impact recommendations for executives to strengthen supply chain resilience, accelerate clinical adoption, and demonstrate value to payers through evidence-driven partnerships

Industry leaders should pursue an integrated strategic approach that aligns product innovation with operational realities and payer expectations. First, prioritizing supply chain resilience through supplier diversification, nearshoring of critical components, and strategic inventory management will mitigate tariff-related and geopolitical risks while preserving launch timelines. Second, investing in clinical training and structured proctoring programs for transfemoral and complex surgical techniques will accelerate safe adoption and reduce variability in outcomes, enabling faster institutional buy-in.

Third, developing modular product platforms that accommodate both balloon-expandable and self-expanding principles and that can be optimized for transfemoral and transapical use will lower lifecycle costs and simplify inventory management for purchasers. Fourth, collaborating proactively with payers to demonstrate total cost of care advantages-through registry participation, real-world studies, and bundled care pilots-will support reimbursement discussions and create pathways for value-based contracting. Finally, committing resources to localized market strategies that combine evidence generation, tailored training, and service support will improve market access and stakeholder trust, especially in regions with heterogeneous regulatory and procurement environments.

Transparent, multi-source research methodology combining clinical literature, registry analytics, and stakeholder interviews to deliver validated insights and credible strategic guidance

This research synthesizes clinical literature, registry data, and primary stakeholder interviews to build a comprehensive understanding of aortic stenosis care dynamics. The methodology combines systematic review of peer-reviewed clinical studies and guideline statements with analysis of procedure-level registries and device safety databases to capture procedural trends and outcome signals. Complementing quantitative sources, structured interviews were conducted with interventional cardiologists, cardiac surgeons, hospital procurement leaders, ambulatory surgical center administrators, and device industry executives to validate assumptions, surface operational constraints, and identify emerging clinical preferences.

Data were triangulated using cross-source validation techniques and subject-matter expert adjudication to ensure interpretive fidelity. Segmentation frameworks were mapped against procedural practice patterns, institutional capabilities, and payer landscapes to produce actionable insights. Recognizing limitations, the methodology accounts for regional variability in registry completeness and acknowledges that evolving clinical trials and regulatory decisions may influence practice over time; as such, findings are presented with transparency regarding data vintage, primary sources, and the scope of primary interviews.

A concise, forward-looking conclusion emphasizing the need for aligned product, clinical, and commercial strategies to convert innovation into scalable improvements in aortic stenosis care

In conclusion, the aortic stenosis landscape is defined by converging clinical innovations, shifting procedural preferences, and heightened attention to value across stakeholders. The interplay between surgical and transcatheter therapies requires manufacturers and providers to pursue complementary strategies that address distinct anatomical and patient-centric needs while streamlining implementation in diverse care settings. Tariff-driven supply chain perturbations and regional regulatory variation further underscore the importance of adaptive manufacturing, robust supplier governance, and localized commercialization plans.

Success in this environment will favor organizations that align product design with clinical workflows, invest in evidence and training, and engage payers with credible value propositions. By synthesizing segmentation, regional nuance, and competitive dynamics, leaders can identify targeted opportunities to optimize portfolios, strengthen partnerships, and deliver demonstrable improvements in patient outcomes and operational efficiency. Continued collaboration across clinical, commercial, and policy stakeholders will be essential to translate technological progress into scalable, sustainable care improvements for patients with aortic stenosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Aortic Stenosis Market, by Product Type

  • 8.1. Surgical Aortic Valve Replacement
  • 8.2. Transcatheter Aortic Valve Replacement
    • 8.2.1. Transapical Approach
      • 8.2.1.1. Left Anterior Mini Thoracotomy
      • 8.2.1.2. Left Anterolateral Mini Thoracotomy
    • 8.2.2. Transfemoral Approach
      • 8.2.2.1. Percutaneous Transfemoral
      • 8.2.2.2. Surgical Transfemoral

9. Aortic Stenosis Market, by Valve Material

  • 9.1. Biological
    • 9.1.1. Bovine
    • 9.1.2. Porcine
  • 9.2. Mechanical
    • 9.2.1. Caged Ball
    • 9.2.2. Tilting Disc

10. Aortic Stenosis Market, by Age Group

  • 10.1. Adult
  • 10.2. Pediatric

11. Aortic Stenosis Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
    • 11.2.1. Community Hospitals
    • 11.2.2. Tertiary Hospitals

12. Aortic Stenosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Aortic Stenosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Aortic Stenosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Aortic Stenosis Market

16. China Aortic Stenosis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 4C Medical Technologies, Inc.
  • 17.6. Abbott Laboratories
  • 17.7. AstraZeneca plc
  • 17.8. B. Braun Melsungen AG
  • 17.9. Biotronik
  • 17.10. Boston Scientific Corporation
  • 17.11. CryoLife, Inc.
  • 17.12. Edwards Lifesciences Corporation
  • 17.13. JenaValve Technology, Inc.
  • 17.14. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.15. LifeNet Health
  • 17.16. LivaNova PLC
  • 17.17. LivaNova PLC
  • 17.18. Medtronic plc
  • 17.19. MicroPort Scientific Corporation
  • 17.20. Venus Medtech (Hangzhou) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AORTIC STENOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AORTIC STENOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AORTIC STENOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AORTIC STENOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AORTIC STENOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL AORTIC VALVE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL AORTIC VALVE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL AORTIC VALVE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTERIOR MINI THORACOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTERIOR MINI THORACOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTERIOR MINI THORACOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTEROLATERAL MINI THORACOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTEROLATERAL MINI THORACOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTEROLATERAL MINI THORACOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PERCUTANEOUS TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PERCUTANEOUS TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PERCUTANEOUS TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AORTIC STENOSIS MARKET SIZE, BY CAGED BALL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AORTIC STENOSIS MARKET SIZE, BY CAGED BALL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AORTIC STENOSIS MARKET SIZE, BY CAGED BALL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TILTING DISC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TILTING DISC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TILTING DISC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AORTIC STENOSIS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AORTIC STENOSIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AORTIC STENOSIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AORTIC STENOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS AORTIC STENOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL AORTIC STENOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 176. GCC AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 177. GCC AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 178. GCC AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 179. GCC AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GCC AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GCC AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 209. G7 AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 210. G7 AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 211. G7 AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 212. G7 AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 213. G7 AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. G7 AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 220. NATO AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 221. NATO AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 222. NATO AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 223. NATO AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 225. NATO AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. NATO AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)